NASDAQ:CGEM Cullinan Oncology (CGEM) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free CGEM Stock Alerts $17.73 +0.95 (+5.66%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$16.69▼$17.7550-Day Range$10.55▼$19.0252-Week Range$7.64▼$19.68Volume244,404 shsAverage Volume472,774 shsMarket Capitalization$763.63 millionP/E RatioN/ADividend YieldN/APrice Target$28.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cullinan Oncology alerts: Email Address Cullinan Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside61.7% Upside$28.67 Price TargetShort InterestHealthy3.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 2 Articles This WeekInsider TradingSelling Shares$1.44 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.55) to ($3.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector388th out of 939 stocksBiological Products, Except Diagnostic Industry59th out of 156 stocks 3.5 Analyst's Opinion Consensus RatingCullinan Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.67, Cullinan Oncology has a forecasted upside of 61.7% from its current price of $17.73.Amount of Analyst CoverageCullinan Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.56% of the float of Cullinan Oncology has been sold short.Short Interest Ratio / Days to CoverCullinan Oncology has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cullinan Oncology has recently increased by 34.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCullinan Oncology does not currently pay a dividend.Dividend GrowthCullinan Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEM. Previous Next 2.6 News and Social Media Coverage News SentimentCullinan Oncology has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cullinan Oncology this week, compared to 1 article on an average week.Search Interest11 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cullinan Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,437,624.00 in company stock.Percentage Held by InsidersOnly 8.82% of the stock of Cullinan Oncology is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cullinan Oncology are expected to grow in the coming year, from ($3.55) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Oncology is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Oncology is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Oncology has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Cullinan Oncology Stock (NASDAQ:CGEM)Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More CGEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEM Stock News HeadlinesMarch 18, 2024 | americanbankingnews.comHC Wainwright Weighs in on Cullinan Oncology, Inc.'s Q2 2024 Earnings (NASDAQ:CGEM)March 16, 2024 | finance.yahoo.comCullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 15, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn SituationMarch 14, 2024 | investorplace.comCGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023March 14, 2024 | finanznachrichten.deCullinan Oncology, Inc.: Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 14, 2024 | benzinga.comCullinan Oncology: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comCullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 1, 2024 | markets.businessinsider.comCullinan Oncology Announces FDA Clearance Of IND Application For CLN-619March 1, 2024 | globenewswire.comCullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple MyelomaFebruary 27, 2024 | globenewswire.comCullinan Oncology to Participate in Upcoming Investor ConferencesFebruary 12, 2024 | investing.comCullinan Oncology LLC (CGEM)January 31, 2024 | finance.yahoo.comChief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology IncJanuary 24, 2024 | finance.yahoo.comInsider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 SharesDecember 18, 2023 | finance.yahoo.comCullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 14, 2023 | finance.yahoo.comCullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesDecember 5, 2023 | msn.comIGM Biosciences to cut 22% of workforce, shut down blood cancer programsNovember 9, 2023 | markets.businessinsider.comCullinan Management’s Financial Solidity and Promising Clinical Trials Underpin Buy RatingNovember 9, 2023 | markets.businessinsider.comCullinan Management: Promising Catalysts and Clinical Trials Propel Buy RatingNovember 9, 2023 | markets.businessinsider.comPromising Cancer Therapy Developments Drive Buy Rating for Cullinan Management’s StockNovember 8, 2023 | msn.comCullinan Oncology GAAP EPS of -$0.91 beats by $0.03November 8, 2023 | benzinga.comRecap: Cullinan Oncology Q3 EarningsNovember 8, 2023 | finance.yahoo.comCullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | morningstar.comCullinan Oncology Inc Ordinary Shares CGEMNovember 3, 2023 | finance.yahoo.comCullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023October 13, 2023 | markets.businessinsider.comPromising Future for Zipalertinib: Buy Rating Justified by Clinical Efficacy, Competitive Landscape, and Investment OpportunitySee More Headlines Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CGEM CUSIPN/A CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees85Year FoundedN/APrice Target and Rating Average Stock Price Target$28.67 High Stock Price Target$34.00 Low Stock Price Target$22.00 Potential Upside/Downside+61.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.11% Return on Assets-30.39% Debt Debt-to-Equity RatioN/A Current Ratio17.07 Quick Ratio17.07 Sales & Book Value Annual Sales$18.94 million Price / Sales40.32 Cash FlowN/A Price / Cash FlowN/A Book Value$10.61 per share Price / Book1.67Miscellaneous Outstanding Shares43,070,000Free Float39,268,000Market Cap$763.63 million OptionableOptionable Beta0.34 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Nadim Ahmed (Age 56)President, CEO & Director Comp: $1.16MMr. Jeffrey Trigilio (Age 40)CFO & Treasurer Comp: $922.61kDr. Jeffrey Jones M.B.A. (Age 53)M.D., M.P.H., Chief Medical Officer Comp: $780.32kDr. Patrick A. Baeuerle Ph.D. (Age 66)Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board Comp: $763.73kDr. Jennifer Michaelson Ph.D. (Age 57)Chief Scientific Officer Ms. Jacquelyn L. Sumer J.D. (Age 46)Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Ms. Rose WeldonSenior Vice President of CommunicationsMr. Steve AndreChief Human Resources OfficerDr. Corinne Savill Ph.D. (Age 65)Chief Business Officer Mr. Kevin A. JohnstonChief Technical Operations OfficerMore ExecutivesKey CompetitorsAllogene TherapeuticsNASDAQ:ALLOExscientiaNASDAQ:EXAINovavaxNASDAQ:NVAXHilleVaxNASDAQ:HLVXPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 82,910 shares on 3/11/2024Ownership: 4.141%Goldman Sachs Group Inc.Bought 42,204 shares on 3/1/2024Ownership: 0.300%American International Group Inc.Bought 972 shares on 2/28/2024Ownership: 2.891%Price T Rowe Associates Inc. MDBought 7,620 shares on 2/16/2024Ownership: 0.051%GSA Capital Partners LLPBought 10,246 shares on 2/16/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions CGEM Stock Analysis - Frequently Asked Questions Should I buy or sell Cullinan Oncology stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEM shares. View CGEM analyst ratings or view top-rated stocks. What is Cullinan Oncology's stock price target for 2024? 4 brokers have issued 1-year price targets for Cullinan Oncology's stock. Their CGEM share price targets range from $22.00 to $34.00. On average, they expect the company's stock price to reach $28.67 in the next twelve months. This suggests a possible upside of 61.7% from the stock's current price. View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts. How have CGEM shares performed in 2024? Cullinan Oncology's stock was trading at $10.19 on January 1st, 2024. Since then, CGEM shares have increased by 74.0% and is now trading at $17.73. View the best growth stocks for 2024 here. Are investors shorting Cullinan Oncology? Cullinan Oncology saw a increase in short interest in March. As of March 15th, there was short interest totaling 935,400 shares, an increase of 34.8% from the February 29th total of 694,100 shares. Based on an average daily volume of 402,300 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.6% of the shares of the company are short sold. View Cullinan Oncology's Short Interest. When is Cullinan Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CGEM earnings forecast. How were Cullinan Oncology's earnings last quarter? Cullinan Oncology, Inc. (NASDAQ:CGEM) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. When did Cullinan Oncology IPO? Cullinan Oncology (CGEM) raised $149 million in an IPO on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Oncology's major shareholders? Cullinan Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Blue Owl Capital Holdings LP (7.99%), Franklin Resources Inc. (7.67%), Vanguard Group Inc. (4.14%), Vanguard Group Inc. (4.14%), Braidwell LP (2.90%) and American International Group Inc. (2.89%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Alan Jones, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2. View institutional ownership trends. How do I buy shares of Cullinan Oncology? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGEM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.